Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

NCT04783935 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Mavenclad®

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany